Fundraising FoxPromedix
Portland, US · Founded 2018 · Oregon corporation · 2 known investors
Find your way into Promedix
Sign up to see every warm intro you have to Promedix
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Promedix team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ProMedix develops the PeriFRL Circulatory Dysfunction Monitor, a device that digitally measures capillary refill time (CRT) to provide standardized, noninvasive monitoring of peripheral perfusion for early sepsis detection and resuscitation. The technology is aimed at clinicians and hospital systems to identify conditions such as septic shock, dehydration, hemorrhage, and cardiogenic shock at the bedside.
Founders & leadership
MH
Matthew HansenCo-Founder
SB
Steven BakerExecutive
SF
Scott FilerExecutiveScott Filer is an executive with nearly three decades of experience in clinical care, life science, and healthcare technology across organizations ranging from 10 to over 1,000 staff. He has held chief executive and strategic leadership roles in clinical research, ambulatory care, rehabilitation, and venture-backed healthcare and biotech companies, with expertise in FDA regulatory approvals, operations, and go-to-market strategy.
DS
David SheridanCo-Founder
RJ
Robert JenksExecutive
AK
Andrew KiblerExecutive
Investors · 2
Elevate Capitallisted by Elevate CapitalPortland · $2M – $25M
How we know: Elevate Capital's portfolio page · Not right? Tell us
Ideashiplisted by IdeashipPortland
How we know: Ideaship's portfolio page · funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$922.8K disclosed across 4 rounds · 2021–2024
▶$200KraisedDec 2024 · 1 investors · BiotechnologyRule 506(b)
▶$200KraisedDec 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew HansenExecutive Officer, Director
- Steven BakerExecutive Officer
- Scott FilerExecutive Officer, Director
- David SheridanExecutive Officer, Director
- Robert JenksExecutive Officer
- Offering amount
- $200K
- Amount sold
- $200K
- First sale
- Dec 2024
- Incorporated
- Corporation, Oregon
- Federal exemptions
- 06b
▶$162.8KraisedSep 2023 · 3 investors · BiotechnologyRule 506(b)
▶$162.8KraisedSep 2023 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David SheridanExecutive Officer, Director
- Steven BakerExecutive Officer
- Matthew HansenExecutive Officer, Director
- Scott FilerExecutive Officer, Director
- Offering amount
- $162.8K
- Amount sold
- $162.8K
- First sale
- Oct 2022
- Incorporated
- Corporation, Oregon
- Federal exemptions
- 06b
▶$310KraisedSep 2023 · 4 investors · BiotechnologyRule 506(b)
▶$310KraisedSep 2023 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Scott FilerExecutive Officer, Director
- David SheridanExecutive Officer, Director
- Steven BakerExecutive Officer
- Matthew HansenExecutive Officer, Director
- Offering amount
- $310K
- Amount sold
- $310K
- First sale
- Oct 2022
- Incorporated
- Corporation, Oregon
- Federal exemptions
- 06b
▶$250KraisedApr 2021 · 1 investors · BiotechnologyRule 506(b)
▶$250KraisedApr 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew KiblerExecutive Officer, Director
- David SheridanExecutive Officer, Director
- Matthew HansenExecutive Officer, Director
- Offering amount
- $250K
- Amount sold
- $250K
- First sale
- Apr 2021
- Incorporated
- Corporation, Oregon, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
RevMedxRevMedx develops hemorrhage-control medical devices, including the XSTAT expanding-sponge injector for junctional bleeding, ratcheting TX tourniquets, and compression wraps. Its products serve licensed medical professionals, first responders, and military users such as US Special Operations Forces.
TrimedxTrimedx is a clinical asset performance company that manages medical devices across health systems using on-site technicians, proprietary datasets, and AI-driven intelligence to optimize device reliability, reduce costs, and enhance security. It serves integrated delivery networks, regional and academic health systems, and community healthcare providers.
Companies working in the same space as Promedix.
Frequently asked questions
- What does Promedix do?
- ProMedix develops the PeriFRL Circulatory Dysfunction Monitor, a device that digitally measures capillary refill time (CRT) to provide standardized, noninvasive monitoring of peripheral perfusion for early sepsis detection and resuscitation. The technology is aimed at clinicians and hospital systems to identify conditions such as septic shock, dehydration, hemorrhage, and cardiogenic shock at the bedside.
- Who are Promedix's investors?
- Promedix's investors include Elevate Capital, Ideaship.
- How much funding has Promedix raised?
- Promedix has disclosed $922.8K raised across 4 rounds.
- Where is Promedix headquartered?
- Promedix is headquartered in Portland, US.